Bio Green Med Solution Inc (BGMS) Stock Price, Quote & News

Company Profile

Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, and fire protection and prevention systems. It also researches and develops pharmaceuticals. The company was formerly known as Cyclacel Pharmaceuticals, Inc. and changed its name to Bio Green Med Solution, Inc. in September 2022. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.

Industry: Biotechnology

Sector: Healthcare

Phone: 60 9 08517 7330

Website: www.bgmsglobal.com

Address:

Level 10, Tower 11 Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia

BeatriceHinze Dec. 15 at 4:52 PM

$BGMS n󠅥󠅒󠅑󠅗󠅣󠅔󠅤󠅓󠅣󠅕󠅖󠅦󠅤󠅔󠅢󠅓󠅤󠅢󠅤󠅨󠅑󠅧󠅔󠅤󠅘󠅒󠅤󠅖󠅔󠅔󠅦󠅘󠅔󠅖󠅤x󠅥󠅒󠅑󠅗󠅣󠅔󠅤󠅓󠅣󠅕󠅖󠅦󠅤󠅔󠅢󠅓󠅤󠅢󠅤󠅨󠅑󠅧󠅔󠅤󠅘󠅒󠅤󠅖󠅔󠅔󠅦󠅘󠅔󠅖󠅤x󠅥󠅒󠅑󠅗󠅣󠅔󠅤󠅓󠅣󠅕󠅖󠅦󠅤󠅔󠅢󠅓󠅤󠅢󠅤󠅨󠅑󠅧󠅔󠅤󠅘󠅒󠅤󠅖󠅔󠅔󠅦󠅘󠅔󠅖󠅤t󠅥󠅒󠅑󠅗󠅣󠅔󠅤󠅓󠅣󠅕󠅖󠅦󠅤󠅔󠅢󠅓󠅤󠅢󠅤󠅨󠅑󠅧󠅔󠅤󠅘󠅒󠅤󠅖󠅔󠅔󠅦󠅘󠅔󠅖󠅤 just gave shorts their dream entry at 1.57 and then instantly ripped 10c+ against them, as long as we hold 1.63 I’m betting they’ll be the ones chasing later 🚀

0 · Reply

ChartChartist Dec. 5 at 10:53 PM

$BGMS i know beautiful $MRNO they’ll pick you up real soon, and with massive volume

0 · Reply

kshonstocks Dec. 5 at 11:48 AM

keep eye on $BGMS off the bottom

0 · Reply

dbr_island Dec. 3 at 4:42 PM

$BGMS there it goes….. 🚨EPOW🚨 just received a $30M contract AH That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰

0 · Reply

DaBullRunner Dec. 1 at 3:45 PM

$SMX watching carefully 🚨TOVX🚨 I’m POUNDING the table here 🚨 They have a multitude of BIG catalysts coming soon This doesn’t belong this low I’m even willing to put some of my TSLA COIN profits into TOVX👇💰💰💰 $KTTA $YXT $BGMS $FLYE let’s get it

0 · Reply

SPYmyQQQ Nov. 25 at 1:16 PM

🎯 Target Hit 🏁 📨 From Nov 18, 2025 💊 $BGMS 💵 Entry: $1.2700 ✅ Ext: $1.4700 💰 P/L: +15.75% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

Bittiesandteer Nov. 18 at 8:40 PM

$BGMS low float and room to move up

0 · Reply

IWillGetThisRight Nov. 18 at 6:19 PM

$BGMS Interesting volume spike here.

0 · Reply

dln101 Nov. 18 at 5:42 PM

$TNON need some news $GLMD style to start bouncing back to $BGMS levels 🤔💪🔥🚀

0 · Reply

d_risk Nov. 13 at 10:05 PM

$BGMS - Bio Green Med Solution, Inc. - 10Q - Updated Risk Factors BGMS warns of shareholder dilution and potential stock price pressure from its FITTERS deal, risks of significant minority influence by FITTERS, integration challenges, exposure to unknown liabilities, and possible earnings volatility or goodwill impairment from acquisition accounting. #Healthcare #EarningsVolatility #MinorityInfluence #ShareholderDilution #AcquisitionRisk 🟢 Added 🟠 Removed https://d-risk.ai/BGMS/10-Q/2025-11-13

0 · Reply

Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update

Aug 13, 2025, 4:05 PM EDT - 4 months ago

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

Aug 4, 2025, 6:50 PM EDT - 4 months ago

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

Jul 15, 2025, 12:17 PM EDT - 5 months ago

Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?

Jul 7, 2025, 6:00 AM EDT - 5 months ago

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

Jul 7, 2025, 6:00 AM EDT - 5 months ago

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

Jul 2, 2025, 9:00 AM EDT - 5 months ago

Cyclacel Pharmaceuticals Announces Stock Split

Jun 20, 2025, 4:30 PM EDT - 6 months ago

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

Jun 3, 2025, 4:15 PM EDT - 6 months ago

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

May 15, 2025, 12:50 AM EDT - 7 months ago

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 7, 2025, 9:00 AM EDT - 7 months ago

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

May 6, 2025, 6:00 AM EDT - 7 months ago

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.

Apr 2, 2025, 4:05 PM EDT - 9 months ago

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Mar 24, 2025, 7:30 AM EDT - 9 months ago

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Feb 27, 2025, 1:38 PM EST - 10 months ago

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Jan 3, 2025, 9:01 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Dec 5, 2024, 4:05 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Nov 14, 2024, 4:15 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 13, 2024, 12:22 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 12, 2024, 4:45 PM EST - 1 year ago

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Oct 24, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Oct 23, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Oct 9, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Sep 25, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

Sep 4, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

Aug 14, 2024, 8:18 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

Jun 26, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

May 14, 2024, 8:08 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript

May 8, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

May 2, 2024, 4:30 PM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 1, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Mar 19, 2024, 6:09 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 4:05 PM EDT - 1 year ago

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Mar 7, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Mar 6, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Feb 20, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

Jan 30, 2024, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Jan 8, 2024, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jan 2, 2024, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

Dec 22, 2023, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

Dec 18, 2023, 9:00 AM EST - 2 years ago

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Dec 12, 2023, 4:05 PM EST - 2 years ago

Cyclacel Pharmaceuticals Announces Reverse Stock Split

Nov 30, 2023, 9:15 AM EST - 2 years ago

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

Nov 28, 2023, 5:15 PM EST - 2 years ago

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

Nov 13, 2023, 7:32 PM EST - 2 years ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript

BeatriceHinze Dec. 15 at 4:52 PM

0 · Reply

ChartChartist Dec. 5 at 10:53 PM

$BGMS i know beautiful $MRNO they’ll pick you up real soon, and with massive volume

0 · Reply

kshonstocks Dec. 5 at 11:48 AM

keep eye on $BGMS off the bottom

0 · Reply

dbr_island Dec. 3 at 4:42 PM

0 · Reply

DaBullRunner Dec. 1 at 3:45 PM

0 · Reply

SPYmyQQQ Nov. 25 at 1:16 PM

🎯 Target Hit 🏁 📨 From Nov 18, 2025 💊 $BGMS 💵 Entry: $1.2700 ✅ Ext: $1.4700 💰 P/L: +15.75% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

Bittiesandteer Nov. 18 at 8:40 PM

$BGMS low float and room to move up

0 · Reply

IWillGetThisRight Nov. 18 at 6:19 PM

$BGMS Interesting volume spike here.

0 · Reply

dln101 Nov. 18 at 5:42 PM

$TNON need some news $GLMD style to start bouncing back to $BGMS levels 🤔💪🔥🚀

0 · Reply

d_risk Nov. 13 at 10:05 PM

0 · Reply

ward007 Nov. 10 at 2:49 PM

$BGMS is anyone here considering this is a reverse merger and once Fitters’ revenue is consolidated, BGMS could look very different from the “biotech shell” most assume it still is?

3 · Reply

bahjatbern Nov. 3 at 6:57 PM

$BGMS 9% profit within one day not bad at all

0 · Reply

TheQueen2014 Nov. 3 at 2:46 PM

$BGMS waiting for pump

0 · Reply

bahjatbern Nov. 3 at 2:18 PM

$BGMS can this reach 20$ with one news ?

1 · Reply

bahjatbern Nov. 3 at 11:52 AM

$BGMS great opportunity to buy ?

0 · Reply

debbiekatz Oct. 30 at 1:25 PM

if you're in $BGMS at 1.75, make sure to use stop loss. the low was 1.54 so should'nt go below that. too many stocks going down and need to use a SL.

0 · Reply

todd9999 Oct. 29 at 10:15 PM

$BGMS whats up with this.

0 · Reply

debbiekatz Oct. 29 at 8:46 PM

$BGMS bottomed out microfloat. very successful type of stock for months now. that's why you hold and keep swinging. posted at 1.75

1 · Reply

bahjatbern Oct. 29 at 7:13 PM

$BGMS clock is ticking

0 · Reply

TheQueen2014 Oct. 29 at 7:08 PM

$BGMS

0 · Reply

acarsoy Oct. 29 at 4:47 PM

$BGMS she knows

0 · Reply

debbiekatz Oct. 29 at 2:50 PM

$BGMS at 1.84. keep swinging. posted here at 1.75

0 · Reply

Market Cap	7.06M
Revenue (ttm)	40,000.00
Net Income (ttm)	-11.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-28,025.00%
Debt to Equity Ratio	0.00

Volume	37,700
Avg Vol	613,140
Day's Range	N/A - N/A
Shares Out	4.90M
Stochastic %K	2%
Beta	-0.19
Analysts	Hold
Price Target	N/A